(Q40550932)

21 September 2017

title

Pharmacologic therapies aid treatment for autism (English)

1 reference

21 September 2017

Pharmacologic Therapies Aid Treatment for Autism (English)

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

30 March 2024

0 references

Ronald L. Lindsay

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14606217

30 March 2024

Michael G. Aman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14606217

30 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14606217

30 March 2024

publication date

1 October 2003

1 reference

full work available at URL

21 September 2017

https://www.healio.com/doiresolver?doi=10.3928/0090-4481-20031001-08

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

30 March 2024

1 reference

21 September 2017

volume

32

1 reference

21 September 2017

issue

10

1 reference

21 September 2017

page(s)

671-676

1 reference

Prevalence of infantile autism in four French regions.

21 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use.

30 March 2024

2

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina.

30 March 2024

4

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism

30 March 2024

5

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children

30 March 2024

11

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

30 March 2024

12

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Intensive behavioral/psychoeducational treatments for autism: research needs and future directions

30 March 2024

13

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation.

30 March 2024

16

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities

30 March 2024

23

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Comorbid anxiety symptoms in children with pervasive developmental disorders.

30 March 2024

24

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.

30 March 2024

25

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation

30 March 2024

26

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.

30 March 2024

27

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Clinical effect of buspirone in autistic children.

30 March 2024

28

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

Treatment with buspirone in a patient with autism.

30 March 2024

29

1 reference

https://api.crossref.org/works/10.3928/0090-4481-20031001-08

30 March 2024

Identifiers

1 reference

21 September 2017

1 reference